New research identifies patient groups most likely to benefit from GLP-1 drugs, offering employers a more clinically driven ...
While thought to be a step in the right direction, more meaningful steps than a name change are seen in revisions to ...
A new five-year model finds GLP-1 users who stayed on treatment at least 12 months generated more projected savings than ...
Dr. Ken Chapman is an industrial-organizational psychologist, author, and founder of Ken Chapman & Associates. With more than ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results